The Week in Review: Oct 26 – Nov 2, 2018

Friday, Nov 2, 2018 News Recap: Report on the Pacific AIDS Network (PAN) 2018 Fall Conference in Kelowna The Pacific AIDS Network held its annual Fall Conference and AGM October 30-31 in Kelowna. HepCBC attended this year for the first time as a Full Member, due to changes in the PAN Constitution and Bylaws. New Bylaws included: PAN no longer requires its hepatitis C organizational members to offer HIV-related services. Aging and Viral Hepatitis ...

Potential markers identified for early detection and prevention of liver cancer

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure—but now a study offers hope of early detection, and targets for new treatments. Published in Frontiers in Cell and Developmental Biology, the results show a dramatic increase in expression of sugar-burning 'glycolytic' enzymes in precancerous cirrhotic livers. This increase is associated with a sign

The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...

FDA OKs First-Line Tx for Unresectable Liver Cancer: First new upfront treatment option in over a decade

WASHINGTON -- The FDA on Thursday approved the kinase inhibitor lenvatinib (Lenvima) for the first-line treatment of hepatocellular carcinoma (HCC) patients with unresectable disease. Approval was based on the REFLECT study, a multicenter non-inferiority trial, which randomized 954 HCC patients 1:1 to either 8 mg or 12 mg oral lenvatinib (depending on the patient's weight) versus 400 mg sorafenib twice daily until disease progression or unacceptable toxic

The Week in Review: April 6 – April 13, 2018

Friday, April 13, 2018 News Recap: Canada: Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...

The Week in Review: March 23 – April 6, 2018

Friday, April 6, 2018 News Recap: HCV – Liver Cancer (HCC): Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C. Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation. Testing for he...

Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C

PARIS — Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation. "Liver cancer is increasing in most Western countries, partly because of the hepatitis C epidemic that occurred in the 1950s and 19

Obesity Linked to Increased Risk of Liver Cancer in Hepatitis B Patients

MedicalResearch.com Interview with: Sang Min Park MD, MPH, PhD:  Chief, Department of Family Medicine, Seoul National University College of Medicine; Director, Health Promotion Center, Seoul National University Hospital; Professor, Department of Biomedical Science & Family Medicine Seoul National University College of Medicine, Seoul, Korea What is the background for this study? What are the main findings? Response: Chronic hepatitis B patients hav

Testing for hepatitis C lags with baby boomers despite high infection rate

Testing for hepatitis C, a major cause of liver cancer, is lagging behind among the group of Americans with the highest rate of infection: baby boomers. A study published Tuesday showed that only about 13 percent of baby boomers were tested in 2015, up just slightly from 12 percent in 2013. U.S. public health authorities recommend all people in that demographic — those born between 1945 and 1965 — be screened for hepatitis C. “If we want to make a dent i

The Week in Review: January 12 – January 19, 2018

Friday, January 19, 2018 News Recap: Research & Discoveries: Blood test for early detection of 8 cancers looks promising. Scientists have developed a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. The test, called CancerSEEK, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests wer...